EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort

Katrin Milger, Hendrik Suhling, Dirk Skowasch, Annette Holtdirk, Nikolaus Kneidinger, Jürgen Behr, Hartmut Timmermann, Christian Schulz, Olaf Schmidt, Rainer Ehmann, Eckard Hamelmann, Marco Idzko und 4 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2023-09 · 11 (9) · 2701-2712.e2

DOI: 10.1016/j.jaip.2023.05.047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-09. Verfasst von Katrin Milger und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine V, University Hospital, LMU Munich, Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Cent…. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Biological Products. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recently, criteria for evaluation of response to biologics have been proposed and the concept of clinical remission has gained attention as a possible goal even in severe asthma. OBJECTIVE: To analyze the response and remission in the German Asthma Net severe asthma registry cohort. METHODS: We included adults not using a biologic at baseline (V0) and compared patients treated between V0 and 1-year visit (V1) without using a biologic (group A) to patients starting with a biologic after V0 and continuing it up to V1 (group B). We applied the Biologics Asthma Response Score to quantify composite response in good, intermediate, or insufficient. We defined clinical remission (R) as absence of significant symptoms (Asthma Control Test score ≥ 20 at V1) in the absence of exacerbations and oral corticosteroid therapy. RESULTS: Group A included 233 and group B 210 patients, the latter receiving omalizumab (n = 33), mepolizumab (n = 40), benralizumab (n = 81), reslizumab (n = 1), or dupilumab (n = 56). At baseline, group B had less often an allergic phenotype (35.2% vs 41.6%), lower Asthma Control Test score (median, 12 vs 14), more exacerbations in the past year (median, 3 vs 2), and more often high-dose inhaled corticosteroid treatment (71.4% vs 51.5%) than group A. After 1 year of treatment, rates of response (good: 61.4% vs 34.8%; intermediate: 26.7% vs 42.9%; insufficient: 11.9% vs. 22.3%) and/or clinical remission (37.6% vs 17.2%) were higher in group B than in group A. CONCLUSIONS: Despite more severe asthma at baseline, patients treated with biologics had a markedly higher probability of achieving good clinical response and/or remission than patients treated without biologics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAsthmaBiological ProductsHumansOmalizumabAdrenal Cortex Hormones

Stichwörter der Autor:innen

Asthma controlBiologicExacerbationsOCS usePulmonary functionRemissionResponseSevere asthmaTreatment

Substanzen

Anti-Asthmatic AgentsOmalizumabAdrenal Cortex HormonesBiological Products

Autor:innen und Institutionen

  • Department of Medicine V, University Hospital, LMU Munich, Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany. Electronic address: Katri…
  • Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
  • Department of Internal Medicine II - Pneumology/Cardiology, University Hospital Bonn, Bonn, Germany.
  • CRO Kottmann, Hamm, Germany.
  • Department of Medicine V, University Hospital, LMU Munich, Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Allergopraxis Hamburg, Hamburg, Germany.

Zitieren

APA

Milger, K., Suhling, H., Skowasch, D., Holtdirk, A., Kneidinger, N., Behr, J., Timmermann, H., Schulz, C., Schmidt, O., Ehmann, R., Hamelmann, E., Idzko, M., Taube, C., Lommatzsch, M., Buhl, R., & Korn, S. (2023). Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort. The Journal of Allergy and Clinical Immunology: In Practice, 11(9), 2701-2712.e2. https://doi.org/10.1016/j.jaip.2023.05.047

Vancouver

Milger K, Suhling H, Skowasch D, Holtdirk A, Kneidinger N, Behr J, et al. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(9):2701-2712.e2. doi:10.1016/j.jaip.2023.05.047

BibTeX
@article{Milger2023,
  author = {Milger, Katrin and Suhling, Hendrik and Skowasch, Dirk and Holtdirk, Annette and Kneidinger, Nikolaus and Behr, Jürgen and Timmermann, Hartmut and Schulz, Christian and Schmidt, Olaf and Ehmann, Rainer and Hamelmann, Eckard and Idzko, Marco and Taube, Christian and Lommatzsch, Marek and Buhl, Roland and Korn, Stephanie},
  title = {Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  volume = {11},
  number = {9},
  pages = {2701--2712.e2},
  doi = {10.1016/j.jaip.2023.05.047}
}
Kostenlos starten →